anti cxcl2 antibody  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: Unveiling the IL-1β/CXCL2 axis: a shared therapeutic target in periodontitis and inflammatory bowel disease

doi: 10.3389/fimmu.2025.1728773

Figure Lengend Snippet: Heterogeneity and functional specialization analysis of myeloid cell (Mye) subpopulations in inflammatory bowel disease. (A) Six subpopulations identified through myeloid cell subcluster analysis and their distribution in healthy controls (HC), Crohn’s disease (CD), and ulcerative colitis (UC). (B) Heatmap of marker gene expression for each subpopulation, where blue represents high expression. (C) Classification of myeloid cells based on marker gene expression into Classical_Mye, Inflammatory_Mye, Complement_Mye, Transcription_Mye, Chemokine_Mye, and Cytotoxic_Mye. (D) Proportion analysis of myeloid cell subpopulations in HC, CD, and UC, with each dot representing an individual sample. (E, F) Density distribution characteristics of inflammatory (E) and chemokine-related (F) myeloid cells in disease states. (G) Chemokine correlation matrix analysis centered on IL1B, where red indicates positive correlation, blue indicates negative correlation, and numerical values represent correlation coefficient r values. (H) Protein-protein interaction (PPI) analysis of chemokine-mediated inflammatory networks. (I, J) UMAP-based spatial mapping analysis showing the expression distribution of neutrophil chemokine CXCL2 across myeloid cell subpopulations in HC, CD, and UC (I) , and highlighting the high CXCL2 expression in transcription-regulatory myeloid cell subpopulations in HC group and the spatially clustered high expression pattern of CXCL2 in inflammatory myeloid cell subpopulations in CD and UC groups (J) .

Article Snippet: Antigen retrieval was performed in citrate buffer at 100°C for 10 min, followed by cooling to room temperature and blocking with 5% bovine serum albumin for 20 min. Primary antibodies against IL1β (16806-1-AP, Proteintech) and CXCL2 (83758-1-RR, Proteintech) were applied and incubated overnight at 4°C.

Techniques: Functional Assay, Marker, Gene Expression, Expressing

Journal: Frontiers in Immunology

Article Title: Unveiling the IL-1β/CXCL2 axis: a shared therapeutic target in periodontitis and inflammatory bowel disease

doi: 10.3389/fimmu.2025.1728773

Figure Lengend Snippet: Expression validation of IL1B and CXCL2 in rat disease models. (A) Serum IL-1β concentration measurements across experimental groups. (B) Serum CXCL2 concentration measurements across experimental groups. (C) Quantitative analysis of IL1B immunohistochemical staining in colonic tissues (%Area). (D) Quantitative analysis of CXCL2 immunohistochemical staining in colonic tissues (%Area). (E-H) Representative micrographs of IL1B expression in colonic tissues across experimental groups (multiple magnifications). (I-L) Representative micrographs of CXCL2 expression in colonic tissues across experimental groups (multiple magnifications). Numbers 1, 2, and 3 represent resolutions of 500μm, 200μm, and 100μm, respectively. Experimental groups: Control, periodontitis (PD), dextran sulfate sodium-induced inflammatory bowel disease (DSS-IBD), and inflammatory bowel disease combined with periodontitis (IBD+PD). Statistical analysis performed using one-way ANOVA with Tukey post hoc test, adjusted p < 0.05 indicates statistical significance. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001.

Article Snippet: Antigen retrieval was performed in citrate buffer at 100°C for 10 min, followed by cooling to room temperature and blocking with 5% bovine serum albumin for 20 min. Primary antibodies against IL1β (16806-1-AP, Proteintech) and CXCL2 (83758-1-RR, Proteintech) were applied and incubated overnight at 4°C.

Techniques: Expressing, Biomarker Discovery, Concentration Assay, Immunohistochemical staining, Staining, Control